Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.

Abstract

Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual patient-level data from the pivotal, phase II, single-arm KarMMa trial (NCT03361748) and aggregate-level data from MAMMOTH, the largest independent observational study of CC in heavily pretreated RRMM patients. Results: Ide-cel improved overall response rate (odds ratio: 5.30; 95% CI: 2.96-9.51), progression-free survival (hazard ratio: 0.50; 95% CI: 0.36-0.70) and overall survival (hazard ratio: 0.37; 95% CI: 0.25-0.56) versus CC. Conclusion: These results suggest ide-cel offers improvements in clinical outcomes relative to CC in this heavily pretreated RRMM population.

• Authors: Nina Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda
• Journal: Journal of comparative effectiveness research (J Comp Eff Res) Vol. 11 Issue 10 Pg. 737-749 (07 2022) ISSN: 2042-6313 [Electronic] England
• PMID: 35485211 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Chimeric Antigen
• idecabtagene vicleucel

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Humans
• Multiple Myeloma (therapy)
• Progression-Free Survival
• Receptors, Chimeric Antigen (therapeutic use)